Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
phosphodiesterase/obésité
Le lien est enregistré dans le presse-papiers
14 résultats
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS REFERENCE TO RELATED APPLICATION
This Application claims the benefit of U.S. Provisional Application Ser. No. 61/444,566 filed Feb. 18, 2011, which is incorporated by reference herein in its entirety.
BACKGROUND OF THE INVENTION
Phosphodiesterases (PDEs) are a class of intracellular enzymes
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Phosphodiesterases (PDEs) are a class of intracellular enzymes involved in the hydrolysis of the nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphates (cGMP) into their respective nucleotide monophosphates. The cyclic nucleotides cAMP and
Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Phosphodiesterases (PDEs) are a class of intracellular enzymes involved in the hydrolysis of the nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphates (cGMP) into their respective nucleotide monophosphates. The cyclic nucleotides cAMP and
Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Phosphodiesterases (PDEs) are a class of intracellular enzymes involved in the hydrolysis of the nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphates (cGMP) into their respective nucleotide monophosphates. The cyclic nucleotides cAMP and
[1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
I. CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority to U.S. Provisional Patent Application No. 61/431,769, filed Jan. 11, 2011, the content of which is hereby incorporated by reference herein in its entirety.
II. FIELD
Provided herein are heteroaryl compounds useful for
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The contents of the text file named SYPA-003_C04US_SeqList_ST25.txt, which was created on Jun. 17, 2015 and is 107 KB in size, are hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION
The present invention relates to the therapeutic use of guanylate cyclase C (GC-C) agonists as
Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
Provided herein are certain aminopyridine and carboxypyridine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by
Pyrazine compounds as phosphodiesterase 10 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
Provided herein are certain pyrazine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10,
Pyrazine compounds as phosphodiesterase 10 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
Provided herein are certain pyrazine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10,
Pyrazine compounds as phosphodiesterase 10 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
Provided herein are certain pyrazine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10,
Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
Provided herein are certain pyridine and pyrimidine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by
Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
Provided herein are certain pyridine and pyrimidine compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by
Piperidine derivative compounds and drugs containing the compounds as the active ingredient
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to a piperidine derivative.
More specifically, the present invention relates to (1) a piperidine derivative of formula (I)
##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of
Combinations
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
COMBINATIONS
The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one active ingredient selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
